Skip to main content

OSE Immunotherapeutics Announces Procedures for Virtual Combined General Meeting

Written by Customer Service on . Posted in Public Companies.

NANTES, France, May 27, 2020 (GLOBE NEWSWIRE) — OSE Immunotherapeutics (ISIN: FR0012127173; Mnémo: OSE) announces the procedures for participating in the Combined General Meeting, to be held on June 16, 2020 at 2:30 p.m. CET.
As indicated in the press release dated May 11, 2020, the Combined General Meeting of June 16, 2020, will be held by live webcast, without the physical presence of shareholders or other persons usually eligible to attend pursuant to the provisions of the ordinances dated March 25, 2020.The prior notice of the General Meeting including the agenda, the resolutions submitted for approval and the main methods of participation and voting, and also serving as notice of the meeting, was published on May 8, 2020 in the French bulletin of mandatory legal announcements (BALO).Login informationThe General Meeting will be webcast live (in French) via a web conferencing system and shareholders of OSE Immunotherapeutics are invited to login through the link:https://channel.royalcast.com/webcast/oseimmunotherapeutics/20200616_1/This link allows shareholders to register for the General Meeting as of today (and until June 16 at 2 p.m. CET) by entering their email address. Registrants will receive a registration confirmation in addition to the ability to add the event to their calendar.On June 16, 2020, shareholders will be able to connect via this same link starting at 2 p.m. CET. The General Meeting will start at 2.30 p.m. and attendees will be able to follow the presentation by OSE Immunotherapeutics’ management on their screens.Due to the closed session, it will not be possible for shareholders to amend resolutions or to propose new resolutions during the General Meeting. The shareholders retain their right to request the inclusion of items or draft resolutions on the agenda and to ask written questions before the General Meeting, in accordance with the regulations in force. Shareholders are invited to send their questions from today and at any time during the presentation to the email address: ag2020@ose-immuno.com. They will be answered during the General Meeting’s Q&A session.Appointment of scrutineersIn accordance with Decree No. 2020-418, the Company’s Board of Directors has decided to appoint the following shareholders as scrutineers:– Mrs. Maryvonne Hiance, shareholder and Vice-Chairman of the Board of Directors;– Mr. Alexis Peyroles, shareholder and CEO of the Company.The General Meeting will be chaired by Mrs. Dominique Costantini, President of the Board of Directors.The Bureau thus constituted will be responsible for ensuring the proper performance of the General Meeting. It will be accompanied by CIC Market Solutions (middle office service of the issuer) which will collect and count the votes of shareholders in registered form or having voted by proxy.Reminder of voting proceduresTo be taken into account, the duly completed and signed forms must be received no later than the fourth day preceding the date of the Meeting, i.e. no later than June 12, 2020.For registered shareholders: they must return the voting form which will be sent to them with the convening notice either by post to CIC Market Solutions (Service Assemblées – 6 Avenue de Provence – 75452 Paris Cedex 09 – France), or by email to the address: serviceproxy@cic.fr.For bearer shareholders: they can request this voting form from the bank or financial intermediary that manages their securities, from the date of notice of meeting. Once completed and signed by the shareholder, the form will be returned to the account-keeping establishment; the latter will send it, along with a certificate of participation, either by post to OSE Immunotherapeutics (22 Boulevard Benoni Goullin 44200 Nantes – France), or by email to the address: ag2020@ose-immuno.com.Shareholders are invited to regularly consult the section dedicated to the General Meeting on the Company’s website: http://ose-immuno.com/documentation/assemblee-generale/ where they will find preparatory documents, including the voting form.ABOUT OSE Immunotherapeutics
OSE Immunotherapeutics is a clinical-stage biotechnology company focused on developing and partnering therapies to control the immune system for immuno-oncology and autoimmune diseases. The company has several scientific and technological platforms including neoepitopes and agonist or antagonist monoclonal antibodies, all ideally positioned to fight cancer and autoimmune diseases. Its first-in-class clinical and preclinical portfolio has a diversified risk profile: Tedopi® (innovative combination of neoepitopes): the company’s most advanced product; positive results for Step-1 of the Phase 3 trial (Atalante 1) in Non-Small Cell Lung Cancer post checkpoint inhibitor failure; due to Covid-19, voluntary definitive suspension of new patient accrual in the Step-2 initially planned in the trial.
In Phase 2 in pancreatic cancer (TEDOPaM, sponsor GERCOR) in combination with checkpoint inhibitor Opdivo®.BI 765063 (OSE-172, anti-SIRPα monoclonal antibody): developed in partnership with Boehringer Ingelheim; myeloid checkpoint inhibitor in Phase 1 in advanced solid tumors.FR104 (anti-CD28 monoclonal antibody): positive Phase 1 results; Phase 2-ready asset in autoimmune diseases or in transplantation.OSE-127 (humanized monoclonal antibody targeting IL-7 receptor): developed in partnership with Servier; positive Phase 1 results; two independent Phase 2 planned in ulcerative colitis (OSE sponsor) and in Sjögren’s syndrome (Servier sponsor) to start in 2020.BiCKI®: bispecific fusion protein platform built on the key backbone component anti-PD-1 (OSE-279) combined with new immunotherapy targets; 2nd generation of PD-(L)1 inhibitors to increase antitumor efficacity. Additional innovative research programs.CoVepiT: a prophylactic vaccine against COVID-19, developed using SARS-CoV-2 optimized neo-epitopes. First preclinical results expected start of H2 2020, possible clinical trial by year end.Due to the COVID-19 crisis, accrual of new patients in the clinical trial TEDOPaM is temporarily suspended and initiation timelines for both Phase 2 trials of OSE-127 could be impacted during the coming months.For more information: https://ose-immuno.com/en/

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.